Topic Issue
Early Diagnosis and Management of Spondyloarthritis MARCH 2018 ĦE VOL. 10 ĦE NO. 2
Diagnosis and Management of Sjogren's Syndrome MARCH 2018 ĦE VOL. 10 ĦE NO. 2
The Use of Glucocorticoids in Rheumatic Diseases MARCH 2018 ĦE VOL. 10 ĦE NO. 2
Behcet's Disease MARCH 2018 ĦE VOL. 10 ĦE NO. 2
Update on Diagnosis and Management of Psoriatic Arthritis NOVEMBER 2017 ĦE VOL. 9 ĦE NO. 7
Comorbidities of Gout APRIL 2017 ĦE VOL. 9 ĦE NO. 3
Updates on the Management of Rheumatoid Arthritis APRIL 2017 ĦE VOL. 9 ĦE NO. 3
Update on the Management of Vasculitides APRIL 2017 ĦE VOL. 9 ĦE NO. 3
Current Understanding of Spondyloarthritis APRIL 2017 ĦE VOL. 9 ĦE NO. 3
Spondyloarthritis: Early Diagnosis and Treatment with Biologics NOVEMBER 2016 ĦE VOL. 8 ĦE NO. 7
Overview of IgG4-related Disease: A Novel Entity JULY 2016 ĦE VOL. 8 ĦE NO. 5
Gout: What is the Treatment Target and How to Achieve the Target? FEBRUARY 2016 ĦE VOL. 8 ĦE NO. 2
Glucocorticoid-induced Osteoporosis FEBRUARY 2016 ĦE VOL. 8 ĦE NO. 2
Role of Musculoskeletal Ultrasound in Diagnosing Arthritis: Insight from New Classification Criteria FEBRUARY 2016 ĦE VOL. 8 ĦE NO. 2
The Era of Biological Therapies in the Management of Psoriasis DECEMBER 2015 ĦE VOL. 7 ĦE NO. 7
Rheumatoid Arthritis and Related Disorders NOVEMBER 2015 ĦE VOL. 7 ĦE NO. 6
Update in the Classification Criteria for Systemic Lupus Erythematous MARCH 2015 ĦE VOL. 7 ĦE NO. 2
Childhood Arthritis: A Review MARCH 2015 ĦE VOL. 7 ĦE NO. 2
The 2010 Rheumatoid Arthritis Classification Criteria MARCH 2015 ĦE VOL. 7 ĦE NO. 2
New Spondyloarthritis Classification Criteria and the Hong Kong Society of Rheumatology Back Pain Referral Guideline MARCH 2015 ĦE VOL. 7 ĦE NO. 2
Biological Therapies in Rheumatic Diseases JANUARY 2015 ĦE VOL. 7 ĦE NO. 1
Overview of Psoriasis for Clinicians NOVEMBER 2014 ĦE VOL. 6 ĦE NO. 7
Glucocorticoid Use in Rheumatology: Mechanism of Action, Adverse Effects and Guidance on Monitoring MARCH 2014 ĦE VOL. 6 ĦE NO. 2
Fibromyalgia MARCH 2014 ĦE VOL. 6 ĦE NO. 2
Immunosuppresants in Systemic Lupus Erythematosus - Treatment Options and Potential Toxicity MARCH 2014 ĦE VOL. 6 ĦE NO. 2
Risks and Benefits of Biologic Agents in Rheumatic Disease MARCH 2014 ĦE VOL. 6 ĦE NO. 2
Selective COX-2 Inhibitors and Non-Selective NSAIDs: A Recap MARCH 2014 ĦE VOL. 6 ĦE NO. 2
Update on Gout Management DECEMBER 2013 ĦE VOL. 5 ĦE NO. 7
Cardiovascular Risk Factors, Morbidity and Mortality in Psoriasis NOVEMBER 2013 ĦE VOL. 5 ĦE NO. 6
Update on Management of Gout and Hyperuricaemia JANUARY 2013 ĦE VOL. 5 ĦE NO. 1
Update on Novel Therapies for Systemic Lupus Erythematosus JANUARY 2013 ĦE VOL. 5 ĦE NO. 1
Update on Treatments in Spondyloarthritis JANUARY 2013 ĦE VOL. 5 ĦE NO. 1
Treat-to-Target in Rheumatoid Arthritis JANUARY 2013 ĦE VOL. 5 ĦE NO. 1
Updates on Systemic Lupus Erythematosus DECEMBER 2012 ĦE VOL. 4 ĦE No. 7
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Clinical Update and Literature Review NOVEMBER 2012 ĦE VOL. 4 ĦE NO. 6
Rheumatoid Arthritis: Advances in Therapeutics MARCH 2012 ĦE VOL. 4 ĦE NO. 2
The Challenge and Essence of the Management of Psoriasis MARCH 2012 ĦE VOL. 4 ĦE NO. 2
Cardiovascular Risk in Patients With Psoriatic Arthritis JANUARY 2012 ĦE VOL. 4 ĦE NO. 1
Safety of Biologic Agents in Inflammatory Diseases DECEMBER 2011 ĦE VOL. 3 ĦE NO. 7
Medical Treatment of Ankylosing Spondylitis JULY 2010 ĦE VOL. 2 ĦE NO. 4
Era of Biologics: Therapeutic Strategies for Rheumatoid Arthritis JULY 2009 ĦE VOL. 1 ĦE NO. 3
This website is restricted for use by medical doctors only.
Disclaimer
| Terms of use | Privacy Statement
Copyright © 2006 The Society of Physicians of Hong Kong.